Last Updated: November 16, 2026

PYRUKYND Drug Patent Profile

« Back to Dashboard


When do Pyrukynd patents expire, and when can generic versions of Pyrukynd launch?

Pyrukynd is a drug marketed by Agios Pharms Inc and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in PYRUKYND is mitapivat sulfate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the mitapivat sulfate profile page.

DrugPatentWatch® Generic Entry Outlook for Pyrukynd

Pyrukynd was eligible for patent challenges on February 17, 2026.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 11, 2035. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for PYRUKYND?
  • What are the global sales for PYRUKYND?
  • What is Average Wholesale Price for PYRUKYND?
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PYRUKYND
Generic Entry Date for PYRUKYND*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for PYRUKYND
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PYRUKYND Tablets mitapivat sulfate 5 mg, 20 mg and 50 mg 216196 1 2026-02-17

US Patents and Regulatory Information for PYRUKYND

PYRUKYND is protected by nine US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of PYRUKYND is ⤷  Start Trial.

This potential generic entry date is based on patent RE49582.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-003 Feb 17, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-003 Feb 17, 2022 RX Yes Yes 10,632,114 ⤷  Start Trial ⤷  Start Trial
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-003 Feb 17, 2022 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-003 Feb 17, 2022 RX Yes Yes 11,234,976 ⤷  Start Trial ⤷  Start Trial
Agios Pharms Inc PYRUKYND mitapivat sulfate TABLET;ORAL 216196-001 Feb 17, 2022 RX Yes No 11,878,049 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for PYRUKYND

When does loss-of-exclusivity occur for PYRUKYND?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 7292
Patent: DERIVADOS DE PIPERAZIN - QUINOLIN SULFONAMIDAS Y COMPOSICIONES FARMACEUTICAS
Estimated Expiration: ⤷  Start Trial

Patent: 2803
Patent: DERIVADOS DE PIPERAZINA COMO MODULADORES DE PIRUVATO QUINASA M2 (PKM2)
Estimated Expiration: ⤷  Start Trial

Australia

Patent: 10266386
Patent: Therapeutic compounds and compositions
Estimated Expiration: ⤷  Start Trial

Brazil

Patent: 1011587
Patent: compostos e composições terapèuticas
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 66882
Patent: COMPOSES ET COMPOSITIONS THERAPEUTIQUES (THERAPEUTIC COMPOUNDS AND COMPOSITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 44788
Patent: COMPOSES, ET COMPOSITIONS ASSOCIEES, QUI MODULENT LA PYRUVATE KINASE M2, ET METHODES DE FABRICATION ASSOCIEES (COMPOUNDS, AND COMPOSITIONS THEREOF, WHICH MODULATE PYRUVATE KINASE M2, AND METHODS OF MAKING SAME)
Estimated Expiration: ⤷  Start Trial

Chile

Patent: 11003350
Patent: Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
Estimated Expiration: ⤷  Start Trial

China

Patent: 2481300
Patent: THERAPEUTIC COMPOUNDS AND COMPOSITIONS
Estimated Expiration: ⤷  Start Trial

Patent: 4817498
Patent: 治疗性化合物和组合物 (Therapeutic compounds and compositions)
Estimated Expiration: ⤷  Start Trial

Colombia

Patent: 80955
Patent: COMPUESTOS TERAPÉUTICOS Y COMPOSICIONES
Estimated Expiration: ⤷  Start Trial

Costa Rica

Patent: 120001
Patent: COMPUESTOS TERAPEUTICOS Y COMPOSICIONES
Estimated Expiration: ⤷  Start Trial

Patent: 170071
Patent: COMPUESTOS TERAPEUTICOS Y COMPOSICIONES
Estimated Expiration: ⤷  Start Trial

Croatia

Patent: 0170955
Estimated Expiration: ⤷  Start Trial

Cyprus

Patent: 19443
Estimated Expiration: ⤷  Start Trial

Denmark

Patent: 48582
Estimated Expiration: ⤷  Start Trial

Ecuador

Patent: 11011567
Patent: COMPUESTOS TERAPÉUTICOS Y COMPOSICIONES
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 48582
Patent: COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES (THERAPEUTIC COMPOUNDS AND COMPOSITIONS)
Estimated Expiration: ⤷  Start Trial

Patent: 41554
Patent: DÉRIVÉS DE QUINOLINE-8-SULFONAMIDE AYANT UNE ACTIVITÉ ANTICANCÉREUSE (QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY)
Estimated Expiration: ⤷  Start Trial

Patent: 08169
Patent: DÉRIVÉS DE 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE AYANT UNE ACTIVITÉ ANTICANCÉREUSE (2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY)
Estimated Expiration: ⤷  Start Trial

Finland

Patent: 0230017
Estimated Expiration: ⤷  Start Trial

France

Patent: C1017
Estimated Expiration: ⤷  Start Trial

Hungary

Patent: 32969
Estimated Expiration: ⤷  Start Trial

Patent: 300018
Estimated Expiration: ⤷  Start Trial

India

Patent: 1DEN2012
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 7277
Patent: תרכובות מאפנני קינאז פירובאט 2m (2pkm) תכשירים המכילים אותן ושימושים בהן (Pyruvate kinase m2 (pkm2) modulator compounds, compositions comprising the same and uses thereof)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 56052
Estimated Expiration: ⤷  Start Trial

Patent: 12532137
Patent: 治療化合物および組成物
Estimated Expiration: ⤷  Start Trial

Patent: 15028083
Patent: 治療化合物および組成物 (THERAPEUTIC COMPOUND AND COMPOSITION)
Estimated Expiration: ⤷  Start Trial

Lithuania

Patent: 48582
Estimated Expiration: ⤷  Start Trial

Patent: 2023513
Estimated Expiration: ⤷  Start Trial

Malaysia

Patent: 1825
Patent: THERAPEUTIC COMPOUNDS AND COMPOSITIONS
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 12000256
Patent: COMPUESTOS TERAPEUTICOS Y COMPOSICIONES. (THERAPEUTIC COMPOUNDS AND COMPOSITIONS.)
Estimated Expiration: ⤷  Start Trial

New Zealand

Patent: 7379
Patent: Therapeutic compounds and compositions
Estimated Expiration: ⤷  Start Trial

Patent: 2505
Patent: Therapeutic compounds and compositions
Estimated Expiration: ⤷  Start Trial

Nicaragua

Patent: 1200003
Patent: COMPUESTOS TERAPÉUTICOS Y COMPOSICIONES
Estimated Expiration: ⤷  Start Trial

Norway

Patent: 23017
Estimated Expiration: ⤷  Start Trial

Peru

Patent: 120693
Patent: COMPUESTOS HETEROCICLOS COMO MODULADORES DE LA PIRUVATO CINASA M2 (PKM2)
Estimated Expiration: ⤷  Start Trial

Poland

Patent: 48582
Estimated Expiration: ⤷  Start Trial

Portugal

Patent: 48582
Estimated Expiration: ⤷  Start Trial

Russian Federation

Patent: 61132
Patent: ЛЕКАРСТВЕННЫЕ СОЕДИНЕНИЯ И КОМПОЗИЦИИ (DERIVATIVES OF CHINOLINESULPHONAMIDES AND THEIR APPLICATION FOR MODULATION OF PKM2 ACTIVITY)
Estimated Expiration: ⤷  Start Trial

Patent: 12102922
Patent: ЛЕКАРСТВЕННЫЕ СОЕДИНЕНИЯ И КОМПОЗИЦИИ (DERIVATIVES OF CHINOLINESULPHONAMIDES AND THEIR APPLICATION FOR MODULATION OF PKM2 ACTIVITY)
Estimated Expiration: ⤷  Start Trial

Singapore

Patent: 201403696U
Patent: THERAPEUTIC COMPOUNDS AND COMPOSITIONS
Estimated Expiration: ⤷  Start Trial

Patent: 201811480W
Patent: THERAPEUTIC COMPOUNDS AND COMPOSITIONS
Estimated Expiration: ⤷  Start Trial

Patent: 7434
Patent: THERAPEUTIC COMPOUNDS AND COMPOSITIONS
Estimated Expiration: ⤷  Start Trial

Slovenia

Patent: 48582
Estimated Expiration: ⤷  Start Trial

South Africa

Patent: 1200054
Patent: THERAPEUTIC COMPOUNDS AND COMPOSITIONS
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 1712035
Estimated Expiration: ⤷  Start Trial

Patent: 1850813
Estimated Expiration: ⤷  Start Trial

Patent: 120107454
Patent: 치료용 화합물 및 조성물 (Therapeutic compounds and compositions)
Estimated Expiration: ⤷  Start Trial

Patent: 170012585
Patent: 치료용 화합물 및 조성물 (Therapeutic compounds and compositions)
Estimated Expiration: ⤷  Start Trial

Spain

Patent: 32954
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 1103913
Patent: Therapeutic compounds and compositions
Estimated Expiration: ⤷  Start Trial

Patent: 1520197
Patent: Therapeutic compounds and compositions
Estimated Expiration: ⤷  Start Trial

Patent: 1731828
Patent: Therapeutic compounds and compositions
Estimated Expiration: ⤷  Start Trial

Patent: 1930288
Patent: Therapeutic compounds and compositions
Estimated Expiration: ⤷  Start Trial

Patent: 72522
Estimated Expiration: ⤷  Start Trial

Patent: 98337
Estimated Expiration: ⤷  Start Trial

Patent: 49313
Estimated Expiration: ⤷  Start Trial

Patent: 91493
Estimated Expiration: ⤷  Start Trial

Ukraine

Patent: 7667
Patent: ЛЕКАРСТВЕННЫЕ СОЕДИНЕНИЯ, СТИМУЛИРУЮЩИЕ АКТИВНОСТЬ ПИРУВАТКИНАЗЫ-М2, КОМПОЗИЦИИ НА ИХ ОСНОВЕ И ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ РАКА (MEDICAL COMPOUNDS STIMULATING ACTIVITY OF PYRUVATE KINASE M2, COMPOSITIONS ON THEIR BASIS AND USE IN THE TREATMENT OF CANCER)
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering PYRUKYND around the world.

Country Patent Number Title Estimated Expiration
Australia 2012250688 ⤷  Start Trial
Australia 2017221860 ⤷  Start Trial
Australia 2020200700 ⤷  Start Trial
Brazil 112013028422 ⤷  Start Trial
Canada 2834602 ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PYRUKYND

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2448582 301230 Netherlands ⤷  Start Trial PRODUCT NAME: MITAPIVAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER MITAPIVATSULFAAT; REGISTRATION NO/DATE: EU/1/22/1662 20221110
2448582 CA 2023 00014 Denmark ⤷  Start Trial PRODUCT NAME: MITAPIVAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER MITAPIVATSULFAT; REG. NO/DATE: EU/1/22/1662 20221110
2448582 2023C/517 Belgium ⤷  Start Trial PRODUCT NAME: MITAPIVAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE SULFATE DE MITAPIVAT; AUTHORISATION NUMBER AND DATE: EU/1/22/1662 20221110
2448582 LUC00306 Luxembourg ⤷  Start Trial PRODUCT NAME: MITAPIVAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR MITAPIVAT SULFATE; AUTHORISATION NUMBER AND DATE: EU/1/22/1662 20221110
2448582 PA2023513 Lithuania ⤷  Start Trial PRODUCT NAME: MITAPIVATAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC MITAPIVATO SULFATAS; REGISTRATION NO/DATE: EU/1/22/1662 20221109
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

PYRUKYND Market Dynamics, Financial Trajectory, Patents, and Competitive Outlook

Last updated: November 16, 2026

Pyrukynd, or mitapivat, is Agios Pharmaceuticals’ first commercial product and the first approved pyruvate kinase activator. The FDA approved it in February 2022 for hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited red-blood-cell disorder. U.S. sales increased from approximately $126.6 million in 2023 to approximately $198.0 million in 2024, according to Agios financial disclosures. Agios guided to 2025 Pyrukynd revenue of approximately $250 million to $260 million.[1][2]

The commercial trajectory depends on three factors: penetration into diagnosed pyruvate kinase deficiency, geographic expansion, and label expansion into thalassemia and sickle cell disease. Thalassemia is the most immediate growth opportunity. Sickle cell disease offers a materially larger market but carries greater clinical, competitive, and reimbursement risk.

What is Pyrukynd and what disease does it treat?

Pyrukynd is an oral small-molecule activator of red-blood-cell pyruvate kinase, the enzyme encoded by the PKLR gene. The drug increases ATP production in red blood cells, improving red-cell survival and reducing hemolysis.

The current approved U.S. indication is treatment of hemolytic anemia in adults with pyruvate kinase deficiency.[3]

Attribute Pyrukynd
Active ingredient Mitapivat
Developer and marketer Agios Pharmaceuticals
Drug class Pyruvate kinase activator
Dosage form Oral tablets
U.S. approval February 17, 2022
U.S. indication Hemolytic anemia in adults with pyruvate kinase deficiency
European approval Granted in 2022
Primary commercial market Pyruvate kinase deficiency
Expansion markets Thalassemia and sickle cell disease
Regulatory pathway New drug application and supplemental indication filings

Pyrukynd is administered orally and is positioned as a disease-modifying treatment rather than a transfusion-support product. Its main commercial advantages are oral administration, potential reduction in transfusion burden, and the absence of a competing approved pyruvate kinase activator.

How large is the Pyrukynd addressable market?

The diagnosed pyruvate kinase deficiency population is small, but treatment value per patient is high. Estimates vary because the disease is underdiagnosed and genetic prevalence is higher than the number of clinically recognized patients.

Agios has described a global patient population of several thousand, with approximately 1,500 to 2,000 diagnosed patients in the United States and Europe combined in earlier commercial estimates. The treated population can expand through genetic testing, hematology-center education, and diagnosis of adults previously classified as having nonspecific hemolytic anemia.

The market has four commercial characteristics:

  1. A rare-disease pricing model with high annual revenue per treated patient.
  2. Concentration of prescribing in specialist hematology centers.
  3. Significant use of patient-support programs and reimbursement services.
  4. A relatively small absolute patient pool that limits the ceiling for the initial indication.

The more important growth markets are thalassemia and sickle cell disease. Both have substantially larger patient populations than pyruvate kinase deficiency, but neither expansion is guaranteed by the initial approval.

What is Pyrukynd’s financial trajectory?

Pyrukynd revenue has followed a steep launch curve.

Fiscal year Pyrukynd net product revenue Commercial status
2022 Approximately $30 million or less, based on the partial launch year U.S. launch and early market access
2023 Approximately $126.6 million Broader U.S. adoption and international contribution
2024 Approximately $198.0 million Continued patient growth and increased treatment duration
2025 guidance Approximately $250 million to $260 million Agios company guidance

The 2023-to-2024 increase was approximately 56%. Agios’ 2025 guidance implies growth of approximately 26% to 31% over 2024.

The initial revenue curve is consistent with a rare-disease launch in which patient identification and reimbursement take time. Revenue growth depends less on mass-market promotion than on finding eligible patients, obtaining genetic confirmation, and converting patients from supportive care or transfusion management.

What drives Pyrukynd revenue growth?

The principal growth drivers are:

  • Increased testing for PKLR mutations.
  • Greater awareness among hematologists.
  • Use in patients with clinically meaningful anemia who have not received regular transfusions.
  • Expansion beyond academic treatment centers.
  • International reimbursement approvals.
  • Longer treatment persistence.
  • New indications with larger patient populations.

The commercial model is also supported by the clinical consequences of chronic hemolysis. Patients with pyruvate kinase deficiency may require transfusions, iron chelation, splenectomy, or management of iron overload. A therapy that reduces transfusion dependence or improves hemoglobin can support a premium price, although payers will evaluate those benefits against uncertain long-term outcomes.

When does Pyrukynd lose exclusivity?

Pyrukynd’s effective loss-of-exclusivity date is not determined by the basic composition-of-matter patent alone. The commercial protection period may include formulation, dosing, use, and regulatory exclusivity rights.

Protection category Relevance to Pyrukynd
Composition-of-matter patents Protect mitapivat and related chemical structures
Pharmaceutical composition patents Protect tablet formulations and drug compositions
Method-of-use patents Protect treatment of PK deficiency and other anemias
Dosing patents May cover titration, maintenance dosing, or treatment regimens
Orphan-drug exclusivity Applies to the approved rare-disease indication for seven years in the U.S.
Pediatric exclusivity May add six months if FDA pediatric requirements are completed
European market exclusivity May include orphan medicinal-product protection and supplementary protection rights

The first U.S. approval received seven years of orphan-drug exclusivity for the PK-deficiency indication under the Orphan Drug Act. That exclusivity generally runs to February 2029, subject to the scope of the designation and any applicable pediatric extension.[3][4]

Patent expiration is likely to extend beyond the orphan-exclusivity period. Public patent records identify multiple Agios-controlled mitapivat patent families covering the active compound, pharmaceutical compositions, and therapeutic uses. The relevant expiry dates vary by family, jurisdiction, patent-term adjustment, and any patent-term extension.

A generic competitor could seek approval before the final patent expiry through a Paragraph IV certification. The practical generic-entry date would depend on the patents listed in the Orange Book, litigation timing, settlement terms, and whether the challenged claims survive review.

What is the Orange Book status of Pyrukynd?

Pyrukynd is an FDA-approved prescription drug and is subject to Orange Book patent-listing analysis. Orange Book-listed patents can create a statutory stay if a branded company files patent-infringement litigation after receiving notice of a Paragraph IV certification.

The strategic importance of Orange Book listings is limited by the size of the market. A generic company must weigh the cost of an abbreviated new drug application, bioequivalence development, patent litigation, and limited patient volume against the potential value of early entry.

Pyrukynd’s risk profile differs from that of a mass-market drug:

  • The market has fewer patients.
  • Prescribing is concentrated among specialists.
  • Generic substitution may be slower in a rare disease.
  • High treatment costs create payer scrutiny.
  • Multiple patent claims may require separate validity and infringement analysis.

No publicly reported Paragraph IV challenge or settlement involving Pyrukynd is identified in the cited company and regulatory materials through the reporting period covered by those sources.[1][2][4]

What formulations and methods of use are protected?

The patent estate is commercially relevant beyond the active ingredient.

Formulation protection

Pyrukynd is marketed as oral tablets in multiple strengths. Formulation claims may cover excipient combinations, tablet composition, stability, and manufacturing processes. These claims can delay simple tablet-copying strategies, although they are usually more vulnerable to design-around arguments than composition-of-matter claims.

Method-of-use protection

The initial method-of-use position covers treatment of hemolytic anemia associated with pyruvate kinase deficiency. Future patents may protect treatment of:

  • Non-transfusion-dependent thalassemia.
  • Transfusion-dependent thalassemia.
  • Sickle cell disease.
  • Specific dosing regimens.
  • Patient subsets with defined hemoglobin or transfusion characteristics.

New indication patents can provide commercial value even after the original compound patent becomes vulnerable. Their value depends on whether a generic label includes the patented use and whether physicians can prescribe the generic for the protected indication through off-label use.

Which companies are challenging Pyrukynd?

No direct approved competitor currently matches Pyrukynd’s mechanism in pyruvate kinase deficiency. Competitive pressure is more likely to arise from alternative treatments and from mitapivat programs targeting larger diseases.

Competitor or alternative Company Target market Competitive status
Chronic transfusion support Blood centers and specialty care providers Thalassemia and severe anemia Established standard of care
Iron chelation Multiple companies Transfusion-related iron overload Adjunctive treatment
Allogeneic stem-cell transplant Transplant centers Selected severe inherited anemias Potentially curative but limited by eligibility and risk
Etavopivat Novo Nordisk, following Forma acquisition Sickle cell disease Clinical-stage pyruvate kinase activation program
Mitapivat follow-on indications Agios Thalassemia and sickle cell disease Primary commercial expansion strategy
Gene therapies Multiple developers Sickle cell disease and thalassemia High-cost alternatives with complex administration

Etavopivat is the most direct mechanism-based competitor in sickle cell disease. It is not an established competitor in PK deficiency. Other competitors include voxelotor-like oxygen-affinity approaches, fetal-hemoglobin inducers, gene therapies, transplant, and supportive care, depending on the disease.

What is the FDA regulatory status of Pyrukynd expansion programs?

Agios is developing mitapivat beyond PK deficiency.

Thalassemia

The phase 3 ENERGIZE and ENERGIZE-T programs evaluated mitapivat in non-transfusion-dependent and transfusion-dependent thalassemia, respectively. Positive results would give Agios access to a larger chronic anemia market and could broaden use among patients already receiving transfusion and iron-management care.

Thalassemia is the most commercially logical expansion because the mechanism applies directly to red-cell energy metabolism and the disease has a defined population managed by specialist hematologists.

Sickle cell disease

The RISE UP development program evaluates mitapivat in sickle cell disease. This market is substantially larger than PK deficiency and has high unmet need, but it is more competitive. Clinical differentiation will depend on effects on vaso-occlusive events, hemolysis, anemia, quality of life, and transfusion requirements.

Sickle cell development also creates greater regulatory risk. A statistically significant improvement in hemoglobin may not be sufficient if regulators require evidence of clinical outcomes or durable benefit.

How strong is the Pyrukynd patent estate?

Pyrukynd has a stronger commercial position than a product protected only by a single use patent because Agios has built protection around the compound, dosage form, and therapeutic applications.

The estate’s strengths are:

  • First-mover status in pyruvate kinase activation.
  • Orphan-drug exclusivity for PK deficiency.
  • Multiple patent families rather than one apparent protection layer.
  • Potential new patents from thalassemia and sickle cell trials.
  • Specialist prescribing, which may reduce immediate generic substitution.

The limitations are:

  • A small initial patient population.
  • Potential Paragraph IV challenges after market value becomes clearer.
  • Difficulty enforcing method-of-use patents against off-label generic use.
  • Possible design-around strategies for formulation claims.
  • Dependence on successful label expansion to support a larger revenue base.

Patent strength is therefore commercially meaningful but not sufficient by itself to support a multibillion-dollar franchise. The valuation case depends primarily on expansion into larger hematologic diseases.

What licensing deals affect Pyrukynd?

Agios retains commercial control of Pyrukynd in key markets. The company’s broader corporate history includes the 2020 sale of its oncology business to Servier, which included oncology assets and associated rights. That transaction is separate from Pyrukynd but affected Agios’ strategic focus and financial resources.[5]

Agios also receives royalty and milestone-related economics from certain former oncology programs. Those revenues have helped fund Pyrukynd commercialization and clinical development, reducing the company’s dependence on external financing.

The central licensing question is whether Agios will commercialize expanded mitapivat indications independently or use regional partnerships. A larger sickle cell launch could require broader sales infrastructure than the current rare-disease model.

What patent litigation and settlement risks affect Pyrukynd?

There is no material publicly reported Pyrukynd patent-litigation settlement in the cited sources. The principal future litigation scenario would involve an ANDA filer submitting a Paragraph IV certification against one or more Orange Book patents.

Potential outcomes include:

  1. Agios sues and obtains a 30-month stay of FDA approval.
  2. The generic applicant prevails on invalidity or non-infringement.
  3. The parties settle for a delayed generic entry date.
  4. The generic enters only for unpatented indications through a skinny label.
  5. A court upholds formulation or dosing claims but invalidates broader compound claims.

The commercial impact of an early generic challenge would be more limited while Pyrukynd remains concentrated in a small rare-disease population. The risk would increase materially if thalassemia and sickle cell approvals expand the addressable market.

How does Pyrukynd compare with other rare-disease drugs?

Pyrukynd has a differentiated profile:

Factor Pyrukynd position
Administration Oral, chronic therapy
Mechanism First approved pyruvate kinase activator
Initial population Very small
Expansion potential High if thalassemia and sickle cell results translate into approvals
Competitive intensity Low in PK deficiency, higher in sickle cell disease
Regulatory risk Moderate for new indications
Patent risk Manageable before later-stage generic challenges
Revenue profile Rapid growth from a low base
Commercial dependency Strongly dependent on diagnosis and label expansion

Compared with gene therapies, Pyrukynd has simpler administration and lower logistical barriers, but it requires chronic dosing. Compared with transfusion and chelation, it may reduce treatment burden but must demonstrate durable clinical and economic value. Compared with other oral hematology therapies, its strongest differentiation is the metabolic mechanism and rare-disease regulatory position.

What generic entry risks exist for Pyrukynd?

The most likely generic-entry window is after the seven-year U.S. orphan-exclusivity period, unless patent litigation or settlements delay entry. The actual date will depend on the surviving Orange Book patents and any patent-term adjustments.

Generic risk is relatively low in the near term because:

  • Pyrukynd has a small but growing market.
  • Specialist adoption creates prescribing inertia.
  • Multiple patents may complicate ANDA approval.
  • New indications could carry separate use patents.
  • Agios can use patient-support and contracting programs to preserve branded demand.

Risk increases if annual sales exceed $500 million through new indications. At that level, the expected value of a Paragraph IV challenge becomes more attractive to generic manufacturers.

Key Takeaways

  • Pyrukynd is the first approved pyruvate kinase activator and Agios’ core commercial asset.
  • U.S. approval occurred in February 2022 for hemolytic anemia in adults with PK deficiency.
  • Revenue increased from approximately $126.6 million in 2023 to approximately $198.0 million in 2024.
  • Agios guided to approximately $250 million to $260 million in 2025 Pyrukynd revenue.
  • PK deficiency alone is a limited market; thalassemia and sickle cell disease determine the product’s long-term value.
  • The patent estate includes compound, formulation, dosing, and method-of-use protection.
  • U.S. orphan exclusivity for the initial indication generally runs into 2029.
  • No material publicly reported Paragraph IV litigation or settlement is identified in the cited sources.
  • The most direct future mechanism-based competitor is etavopivat in sickle cell disease.
  • Generic risk is limited in the near term but could rise sharply if label expansion creates a larger revenue opportunity.

FAQs

Is Pyrukynd a biologic or a small-molecule drug?

Pyrukynd is an orally administered small-molecule drug. It is not a biologic and is not subject to the biosimilar approval pathway.

Does Pyrukynd have an approved indication for sickle cell disease?

No. The approved U.S. indication is hemolytic anemia in adults with pyruvate kinase deficiency. Sickle cell disease remains an expansion-development opportunity.

What is the main commercial risk for Pyrukynd?

The main risk is failure to convert clinical development into approvals for larger indications. The PK-deficiency market alone limits the product’s ultimate revenue ceiling.

Can a generic company launch mitapivat before 2029?

A generic company could seek approval before the orphan-exclusivity date through a patent challenge, but commercial launch would depend on patent litigation, Orange Book protections, settlement terms, and FDA approval timing.

Why is thalassemia important to Agios?

Thalassemia has a larger patient population than pyruvate kinase deficiency and includes patients with chronic transfusion and iron-overload burdens. A successful approval would expand mitapivat’s revenue base without requiring the broader commercial infrastructure needed for sickle cell disease.

References

  1. Agios Pharmaceuticals, Inc. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.

  2. Agios Pharmaceuticals, Inc. (2025). Fourth-quarter and full-year 2024 financial results and 2025 financial guidance. Agios Pharmaceuticals.

  3. U.S. Food and Drug Administration. (2022). Pyrukynd (mitapivat) prescribing information. FDA.

  4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

  5. Servier and Agios Pharmaceuticals. (2020). Servier completes acquisition of Agios oncology business. Servier.

More… ↓

⤷  Start Trial

DrugChatter Q&A for PYRUKYND

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.